long-acting insulin analogue
Insulin degludec
Answer
Insulin degludec is authorised or registered in the US, the EU, the UK, Canada, Australia, Switzerland, Brazil, Serbia, Singapore and Turkey: 10 of the 10 registers read. Highest trial phase: Phase 4 (after approval). It has 255 registered trials, 17 of them running. Brand names on the FDA label register: Xultophy 100/3.6, Tresiba and Insulin Degludec.
RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
255 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 95 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 127 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Authorised | EMA, ema | 2026-10-03 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-10-03 |
| Australia | Registered | TGA, au-artg | 2026-10-03 |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Authorised | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
CHANGE ALERTS
Get an email when this changes
One email when the status of Insulin degludec changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 255 trials
| NCT07630233 | A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in H currently recruiting participants · register updated 2026-09-15 |
|---|---|
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study running, but no longer enrolling · register updated 2026-08-13 |
| NCT04760626 | A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 completed · register updated 2026-08-11 |
| NCT06238778 | Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec completed · register updated 2026-07-31 |
| NCT07652528 | CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hyperglycemia in Sudden Sensorineural Hearing Loss: SHIP Trial not yet recruiting participants · register updated 2026-07-22 |
| NCT07215312 | A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin running, but no longer enrolling · register updated 2026-07-13 |
| NCT07527078 | Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes currently recruiting participants · register updated 2026-07-01 |
| NCT04795531 | A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in Peo completed · register updated 2026-06-12 |
| NCT06288412 | A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fas completed · register updated 2026-06-08 |
| NCT07599891 | Comparing the Safety and Efficacy of Insulin GLARGINE and DEGLUDEC in Glucocorticoid Induced HYPERGLYCEMIA in Hospitalized Patient completed · register updated 2026-05-20 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.